Financials
Financial year 2024
Worth noting
- More debts than assets in the latest financial year.
- A loss two years in a row.
- Little cash and receivables against the short-term debts.
Gross margin
€ 393,338
▼ 85% vs 2023
Profit
Caution€ -3 million
▼ 1018% vs 2023
Debts
High€ 11.2 million
▲ 18% vs 2023
ImmunXperts from Charleroi, company number BE0552755587, closed financial year 2024 with a result of € -3 million after tax. For that financial year ImmunXperts recorded a gross margin of € 393,338 and equity of € -1.6 million. Compared with financial year 2023, the result moved from € -266,255 to € -3 million. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on July 8, 2025.
What happened at ImmunXperts?
What happened at ImmunXperts in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Sofie Pattyn stepped down as director. NBB
- Clément Vanthournhout stepped down as director. NBB
- Emmanuel Vanderhaegen stepped down as director. NBB
- New annual accounts for financial year 2024: loss of € 3 million. Source: NBB ↗
- Emmanuel Vanderhaegen became a director. NBB
- Sofie Pattyn became a director. NBB
- Clément Vanthournhout became a director. NBB
- New establishment in Charleroi. KBO
In short
From € 238,014 profit in 2021 to € 3 million loss in 2024.
Paid € 5,413 in corporate taxes since 2021.
Best year ever: 2022, with € 458,486 profit.
On average € 14,700 of value added per employee in 2024.
A new publication or filing at ImmunXperts? We notify you, reason included.
Follow ImmunXpertsNeed more data?
History
Every financial year, as far back as the National Bank goes.
Buffer
How long does the company survive without income?
Credit limit
Indicative credit limit, computed from the real figures.
Alerts
News about who you follow, reason included.
Then €29.99/mo excl. VAT, cancel monthly. No credit card to try; the AI assistant is not included, or only in a very limited form, during the trial month. Sign up now and you’ll be invited first.
Management
The shares are held by Nexelis Europe (100%).
Directors
According to the 2024 annual accounts
since 2022 · until 2028
since 2022 · until 2028
Emmanuel Vanderhaegen
Director
since 2023 · until 2028
Shareholders
100%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Rue Clément Ader 10
6041 Charleroi
Rue Clément Ader 16
6041 Charleroi
Active since 16 May 2014
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 31 companies are registered at this address.
Brussels South Charleroi BioPark Dev
€ 80,186 gross margin · 2025
LYS MEDICAL
€ -309,203 gross margin · 2025
SPECTRALYS BIOTECH
€ 143,689 gross margin · 2025
ProtonW.be
€ -7,643 gross margin · 2025
QbD Wallonia
€ 1.5 million gross margin · 2025
+26 more
Website
Technologies
Hosting & Email
Email provider
Microsoft 365
Hosting
AS-26496-GO-DADDY-COM-LLC - GoDaddy.com, LLC, US
Domain
Domain
immunxperts.com
Registered
2013-06-12
Registrar
GoDaddy.com, LLC
Expires
2026-06-12
Website info
Features
Security
Details
- Company number
- 0552.755.587
- VAT number
- BE 0552.755.587
- Registered office
- Rue Clément Ader 10, 6041 Charleroi
- Names & denominations
- ImmunXperts · IMXP
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 16 May 2014
- Peppol
- Active · Active since 1 Jan 2001
- Contact
- immunxperts.com
- Activities · NACE
Speur- en ontwikkelingswerk op biotechnologisch gebied